NASDAQ:ALXO

Alx Oncology Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy ALXO

*Your capital is at risk

$1.67

-0.110 (-6.18%)

At Close: Jun 03, 2026

ALX Oncology Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 97.53. In total, the insiders bought 13.41M and sold 69.93K ALXO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	97.53
● Buy	13.41M shares
● Sell	69.93K shares
75% Buy Activity Weak Negative Correlation
Buy Signal Medium Confidence Feb 02, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 97.53. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 16, 2026 Buy	Stock option (right to buy) A-Award	Klencke Barbara Chief Medical Officer	Officer	100 000 Value: $168.0K
Apr 16, 2026 Buy	Stock option (right to buy) A-Award	Knight Jeff E. Chief Dev & Operating Officer	Officer	800 000 Value: $1.34M
Apr 13, 2026 Buy	Common Stock J-Other	Knight Jeff E. Insider	Other	0 Value: $0
Mar 19, 2026 Sell	Common Stock S-Sale	Pinto Shelly SVP, Finance And Cao	Officer	903 Value: $2K
Mar 19, 2026 Sell	Common Stock S-Sale	Lettmann Jason Chief Executive Officer	CEO / President	12 311 Value: $26.7K
Mar 03, 2026 Buy	Stock option (right to buy) A-Award	Klencke Barbara Chief Medical Officer	Officer	700 000 Value: $1.45M
Feb 25, 2026 Buy	Stock option (right to buy)	Klencke Barbara Chief Medical Officer	Officer	300 000 Value: $315.0K
Feb 25, 2026 Buy	Common Stock	Klencke Barbara Chief Medical Officer	Officer	0 Value: $0
Feb 25, 2026 Buy	Stock option (right to buy)	Klencke Barbara Chief Medical Officer	Officer	40 400 Value: $66.7K
Feb 25, 2026 Buy	Stock option (right to buy)	Klencke Barbara Chief Medical Officer	Officer	100 000 Value: $148.0K
Feb 18, 2026 Sell	Common Stock S-Sale	Pinto Shelly SVP, Finance And Cao	Officer	565 Value: $1K
Feb 17, 2026 Sell	Common Stock F-InKind	Lettmann Jason Chief Executive Officer	CEO / President	2 201 Value: $5K
Feb 02, 2026 Buy	Common Stock P-Purchase	Goodman Corey S	Director	3 184 713 Value: $5.00M
Jan 26, 2026 Buy	Stock option (right to buy) A-Award	Lettmann Jason Chief Executive Officer	CEO / President	912 000 Value: $1.35M
Jan 26, 2026 Buy	Stock option (right to buy) A-Award	Shantharam Harish Chief Financial Officer	C-Suite Officer	303 000 Value: $448.4K
Jan 26, 2026 Buy	Stock option (right to buy) A-Award	Pinto Shelly SVP, Finance And Cao	Officer	192 000 Value: $284.2K
Jan 20, 2026 Buy	Stock Option (right to buy) A-Award	Curran Daniel J. Director	Director	16 833 Value: $22.2K
Jan 20, 2026 Buy	Stock option (right to buy) A-Award	Garland J. Scott Director	Director	40 400 Value: $53.3K
Jan 20, 2026 Buy	Stock Option (right to buy) A-Award	Goodman Corey S	Director	40 400 Value: $53.3K
Jan 20, 2026 Buy	Stock option (right to buy) A-Award	Sandler Alan B. Director	Director	10 100 Value: $13.3K
Jan 20, 2026 Buy	Stock option (right to buy) A-Award	Takimoto Chris H Director	Director	40 400 Value: $53.3K
Jan 20, 2026 Buy	Stock option (right to buy) A-Award	Hemrajani Rekha Director	Director	40 400 Value: $53.3K
Jan 06, 2026 Sell	Common Stock S-Sale	Pinto Shelly SVP, Finance And Cao	Officer	3 925 Value: $4K
Oct 14, 2025 Buy	Employee Stock Option (right to buy) A-Award	Shantharam Harish Chief Financial Officer	C-Suite Officer	198 750 Value: $337.9K
Oct 14, 2025 Buy	Employee Stock Option (right to buy) A-Award	Lettmann Jason Chief Executive Officer	CEO / President	597 500 Value: $1.02M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALX ONCOLOGY HOLDINGS INC.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell c...

Read Full Profile Here